We focused on immuno-labeling of clinically relevant target—human norepinephrine transporter (hNET), which is over-expressed in neuroendocrine tumors like neuroblastoma, and which is targeted by one of the most widely used theranostic agent metaiodobenzylguanidine (mIBG) [21]. The gene discussed is SLC6A2; the disease is neuroendocrine neoplasm.